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Abstract
Objective. To evaluate the potential role of CC chemokine receptor 5 (CCR5)D32 polymorphism in the
susceptibility to and clinical expression of Behc¸et’s disease (BD) in a cohort of Italian patients.
Methods. One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were
followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped
for the CCR5D32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype
HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical
manifestations.
Results. The distribution of theCCR5D32 genotype differed between BD patients and controls (P=0.02). The
CCR5D32 allele was more common in BD patients than in controls [P=0.02, odds ratio (OR) 2.28 (95%CI 1.1,
4.8)]. Carriers of the CCR5D32 allele (D32/D32+CCR5/D32) were significantly more common in BD patients
than in controls [P=0.02, OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing
patients according to gender, the association between CCR5D32 polymorphism and BD was similar in fe-
males andmales (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies
of clinical manifestations were compared between CC5RD32 allele carriers and non-carriers.
Conclusion. CCR5D32 polymorphism is associated with an increased susceptibility to develop BD.
Chemokines may have a role in the pathophysiology of BD.
Key words: Behc¸et’s disease, CC chemokine receptor 5 !32 polymorphism, disease manifestations,
chemokines.
Introduction
Behc¸et’s disease (BD) is a primary systemic vasculitis of
unknown aetiology that may affect venous and arterial
vessels of any size [1]. The hallmark manifestation of BD
is oral aphthosis, often associated with genital aphthae
and various skin lesions [1]. Vascular, ocular and internal
organ involvement occurs less frequently, but contributes
substantially to morbidity and mortality [1]. Approximately
one-third of BD patients develop thrombophlebitis of the
deep or superficial veins (usually of the lower extremities),
whereas arterial disease is distinctly less common (<5%
of cases) [1, 2].
The pathogenesis of BD is still debated, but is likely to
involve complex interactions between T cells, neutrophils
and antigen-presenting cells [3]. In particular, mechan-
isms that may be operating include neutrophil hyperactiv-
ity [3], alteration of innate and adaptive immunity such as
T helper 1 (Th1) [3, 4] and Th17 polarization [5] and exces-
sive cytokine [4, 5] and chemokine production [4].
Chemokines and their receptors play an important role
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in the selective recruitment of various subsets of
leucocytes to affected sites in various autoimmune con-
ditions [6].
In BD, increased expression of the Th1-associated CC
chemokine receptor type 5 (CCR5) and CXCR3 has been
demonstrated in mucosal samples, suggesting a patho-
genic role for Th1 lymphocytes [4]. CCR5 is a G protein-
coupled receptor expressed on Th1 cells, monocytes and
dendritic cells [6]. CCR5 ligands include the chemokines
CCL3 [chemokine (C-C motif) ligand 3, also known as
macrophage inflammatory protein-1a], CCL4 (also
known as macrophage inflammatory protein-1b) and
CCL5 [also known as RANTES (regulated on activation,
normal T cell expressed and secreted)] [6]. CCR5 en-
gagement by its ligands mediates mononuclear cell mi-
gration to sites of inflammation and has been implicated
in the pathogenesis of various immune-mediated diseases
[6]. CCR5 is also a major port of entry for
macrophage-tropic HIV strains into host cells in associ-
ation with CD4 [6]. The CCR5 gene polymorphism (a
32-bp deletion in the CCR5 gene CCR5D32) leads to a
non-functional surface receptor that is unable to bind to
its natural ligands [6].
The CCR5D32 allele has been linked to a number of
immunological diseases, including RA and sarcoidosis
[7!8]. With regard to BD, no association with the
CCR5D32 polymorphism was found in British, Turkish or
Palestinian patients [9], whereas an increased frequency
of this polymorphic variant was found in Iranian patients
[10]. The aim of our study was to investigate the potential
impact of the CCR5D32 polymorphism on the susceptibil-
ity to and clinical expression of BD in a cohort of Italian
patients.
Materials and methods
Study population
The study comprises 196 BD patients, recruited consecu-
tively, who were followed in nine different Italian referral
centres for 8 years (1999!2007). All patients fulfilled the
International Study Group for BD (ISG) criteria [11]. The
control group consisted of 180 healthy, age- and gender-
matched, unrelated blood donors with a mean age of
42±13 years.
All study subjects were Caucasians who had been resi-
dent in Italy for at least one generation. There were no
ethnic differences between patients and controls. The
diagnosis of subcutaneous thrombophlebitis (ST) and
deep vein thrombosis (DVT) was based on clinical data
and confirmed in all patients by ultrasonography or con-
trast venography. In most of the patients with erythema
nodosum, ultrasonographic examination was performed
to help in the differential diagnosis between superficial
thrombophlebitis and erythema nodosum. The study
was approved by the ethics committees of Reggio
Emilia, and written informed consent was obtained from
patients and controls before study entry.
HLA class I typing
A standard microlymphocytotoxicity technique was used
to serotype HLA class I alleles in peripheral blood lympho-
cytes. One hundred and ninety-four of the 196 patients
were typed for the HLA-B51 allele. The control group con-
sisted of the same 180 healthy unrelated blood donors
used for the CCR5D32 assays.
Molecular analysis of CCR5D32 polymorphism
DNA extraction was performed using a Genomic DNA
Purification Kit (Gentra Systems, Inc., Minneapolis, MN,
USA) from peripheral white blood cells. Genotyping of
CCR5D32 polymorphism comprised a one-step PCR
method with forward primer 50-TCTTCATTACACCTGCA
GCTC-30 and reverse primer 50-CTCACAGCCCTGTGCC
TCTTC-30 flanking of the region containing the 32-bp de-
letion. The PCR products were analysed by 2.5% agarose
gel electrophoresis. The normal allele was detected as a
137-bp fragment and the d32 allele was detected as a
105-bp fragment [12]. In each analysis, three samples
with known genotype were added; the genotype control
samples were confirmed each time, demonstrating that
the procedure was highly reproducible.
Statistical analysis
Statistical analysis was done using the SPSS statistical
package (SPSS Inc., Chicago, IL, USA; version 14.0,
2006). The frequencies of the alleles and genotypes
among the case patients and control group were com-
pared by !2 test. Fisher’s exact test was used when the
minimum expected value was <5. Odds ratios (ORs) were
calculated together with their 95% CI. To determine P-
values we used asymptotic lookup distribution with con-
tinuity correction. The cases and controls were tested for
conformity to the Hardy!Weinberg equilibrium using a
2! 2 !2 test between observed and expected numbers.
To identify potential genotype!phenotype correlates, we
compared patients with and without specific clinical mani-
festations according to CCR5/D32 carrier status and com-
pared with healthy controls.
The population-attributable risk percentage (PAR%) for
the risk genotype (D32/D32 and CCR5/D32) was esti-
mated with the following formula:
PAR % ¼ PeðRR$ 1Þ=½PeðRR$ 1Þ þ 1(,
where Pe represents the risk genotype frequency in the
population and RR represents the relative risk of the risk
genotype [13]. Given the low prevalence of BD, Pe can be
estimated based on the genotype frequencies in healthy
controls and RR can be approximated by OR for the risk
genotypes. Power testing was performed using PAWE
software: at a significance level of 0.05, power was 0.89
for the allelic test and 0.82 for the genotypic test (PAWE;
http://linkage.rockefeller.edu/pawe/pawe.cgi).
Results
Table 1 shows the demographic and clinical characteris-
tics of the 196 Italian patients with BD. A total of 50
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patients (25.5%) had thrombosis, 35 of whom had DVT
of the legs (17.9%) and 20 who had ST (10.25%). Two
patients had isolated intracardiac thrombosis, and one
had Budd!Chiari syndrome as well as extensive inferior
vena cava and leg vein thromboses. None of the patients
had arterial involvement. There were no significant differ-
ences in the demographic and clinical characteristics of
the patients with and without DVT (data not shown).
Populations of controls and cases were tested for
Hardy!Weinberg equilibrium: genotype frequencies of all
populations did not reject Hardy!Weinberg equilibrium.
The allele and genotype frequencies of the CCR5D32
polymorphism in BD patients and in healthy controls are
shown in Table 2. The distribution of the CCR5D32 geno-
type differed significantly between BD patients and con-
trols (P=0.024). The distribution of the genotype in the
CCR5D32 polymorphism indicated that the differences in
allele distribution were related to a higher frequency of
CCR5/D32 heterozygosity in BD patients as compared
with controls. The D32/D32 homozygosity was not
observed in either BD patients or in the control group.
The CCR5D32 allele was significantly more common in
BD patients than in controls [P=0.020; OR 2.28 (95%
CI 1.1, 4.8)]. Carriers of the CC5RD32 allele (D32/
D32+CCR5/D32) were significantly more frequent in the
BD patient group than in the control group [P=0.024, OR
2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was
7.1%.
Because one study [10] has shown that the influence of
the CCR5D32 polymorphism could be gender specific, we
compared the distribution of the CCR5D32 allele in BD
females and BD males. Carriers of the CC5RD32 allele
(D32/D32+CCR5/D32) were significantly more common
in the BD females than in the control group [14% vs
5.6%, P=0.018, OR 2.76 (95% CI 1.2, 6.6)]. Carriers of
the CC5RD32 allele were also more common in BD males
than in controls, but the difference was not statistically
significant [10.7% vs 5.6%, P=0.091, OR 2.0 (95% CI
0.8, 5.0)].
The possible associations between the CCR5D32 poly-
morphism and the clinical manifestations of BD shown in
Table 1 were evaluated in the 196 BD patients by compar-
ing the frequencies of clinical manifestations between
CC5RD32 allele carriers and non-carriers; no significant
differences were found. ST was more common in the car-
riers of the CC5RD32 allele, but the difference was not
statistically significant. HLA-B51 allele frequency was sig-
nificantly higher in BD patients compared with healthy
controls [67.0% vs 18.8%, P=0.0001, OR 8.72 (95% CI
5.4, 14.0)].
Discussion
The CCR5 gene has a 32-bp deletion (!32) polymorphism
in its promoter region resulting in a non-functional CCR5
protein [6]. CCR5D32 homozygous subjects do not ex-
press the receptor on the cell surface, whereas heterozy-
gotes express lower amounts of the receptor than
wild-type homozygotes [6]. In humans, CCR5D32 poly-
morphism has been linked to a wide range of diseases.
TABLE 1 Demographic and clinical features of 196 Italian patients with BD: all patients and according to CCR5/D32
carrier status
Demographic/clinical features BD (n=196)
D32/D3 D32+
CCR5/D32 (n=24)
CCR5/CCR5
(n=172) P
Mean age at disease onset (S.D.), years 30±12
Mean disease duration (S.D.), years 11±8
Male/female 103 (52.6)/93 (47.4) 11 (45.8)/13 (54.2) 92 (53.5)/80 (45.6) 0.482
Oral ulcers 196 (100) 24/24 (100) 172/172 (100) 0.102
Cutaneous lesions 161 (82.1) 20/24 (83.3) 141/172 (82.2) 0.871
Papulopustular lesions 105 (53.6) 13/24 (54.2) 92/172 (53.5) 0.950
Erythema nodosum 79 (40.3) 8/24 (33.3) 71/172 (41.3) 0.457
Genital ulcers 117 (59.7) 12/24 (50.0) 105/172 (61.0) 0.301
Epididymitis 14 (7.1) 2/24 (8.3) 12/172 (7.0) 0.809
Eye lesions 110 (56.1) 15/24 (62.5) 95/172 (55.2) 0.502
Anterior uveitis 62 (31.6) 7/24 (29.2) 55/172 (32.0) 0.782
Posterior uveitis/retinal vasculitis 85 (43.4) 11/24 (45.8) 74/172 (43.0) 0.795
Arthritis 82 (41.8) 8/24 (33.3) 74/172 (43.0) 0.367
Central nervous system involvement 32 (16.4) 6/24 (25.0) 26/171 (15.2) 0.225
Total venous thrombosisa 50 (25.5) 7/24 (29.2) 43/172 (25.0) 0.661
DVT 35 (17.9) 5/24 (20.8) 30/172 (17.4) 0.684
ST 20 (10.2) 5/24 (20.8) 15/172 (8.7) 0.066
Positive pathergy testb 42/101 (41.6) 4/10 (40.0) 38/91 (41.8) 0.915
HLA-B51c 130/194 (67.0) 19/24 (79.1) 111/170 (65.3) 0.261
Data presented as number (%) unless otherwise noted. aDVT + ST. bPathergy test performed on 101 patients. cHLA-B51 was
performed on 194 patients.
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For some diseases, CCR5D32 carriage appears to be a
protective factor, being associated with a reduced risk in
some rheumatic disease such as primary SS [14] and RA
[7]. In contrast, other studies have mapped CCR5D32 to
increased susceptibility to or greater severity of inflamma-
tory conditions such as chronic periaortitis [15], granulo-
matosis with polyangiitis [16] and sarcoidosis [8].
With regard to BD, one study found no association be-
tween the CCR5D32 polymorphism and BD in British,
Turkish or Palestinian patients [9], whereas another
study reported an association between CCR5D32 and
BD in Iranian women, but not in men [10].
In our study, we found a positive association between
the CCR5D32 allele and BD in a large cohort of Italian
patients. In categorizing patients according to gender,
the association between CCR5D32 polymorphism and
BD was similar in females and males (ORs 2.76 and 2.0,
respectively). The reason for the discrepancies in the
above findings is not entirely clear, but may be related
to the sizes and types of the study populations. Sample
size is a major issue in many studies investigating poly-
morphisms, with both type 1 and 2 errors being more
likely to occur in smaller study populations. On the
other hand, the association between the CCR5D32 allele
and BD may be a genuine finding, but limited to one or
some ethnic groups. Either way, caution is advised
when interpreting our results and those from previous stu-
dies [9, 10].
We could ask how the CCR5D32 allele impacts on the
susceptibility to develop BD. In wild-type individuals,
CCR5 mediates mononuclear cell recruitment to sites of
inflammation by interacting with its ligands CCL3, CCL4
and CCL5. However, these ligands are also able to bind to
other receptors. Specifically, CCL3 can also bind to CCR1
and CCR4, CCL4 to CCR1 and CCR8, and CCL5 to
CCR1, CCR3 and CCR4 [6]. It has been shown that in
the absence of a functional CCR5, its ligands can undergo
up-regulation and exert their biological effects by enga-
ging other available receptors. For instance, in nephro-
toxic serum nephritis, CCR5-deficient (CCR5$/$) mice
express higher intrarenal levels than wild-type strains of
CCL3 and CCL5, which appear to correlate with the infil-
tration of interferon-g-producing CD4+ Th1 cells in the
kidneys [17]. This Th1 response can be abrogated by
CCR1 blockade, suggesting that both CCL3 and CCL5
act by engaging CCR1 [17!20]. Similarly, increased
CCL4 synthesis has been described in CCR5$/$
mice with collagen-induced arthritis [18], whereas in
CCR5$/$ mice with autoimmune uveoretinitis, overex-
pression of CCL5 has been linked to augmented
intra-ocular production of IL-6 and greater neutrophil infil-
tration compared with wild-type mice [19]. Furthermore, it
has been demonstrated that lymphocytes from CCR5D32
homozygous subjects secrete RANTES at levels that are
5!10 times higher than those of control CCR5 homozy-
gous subjects [20]; the elevated levels of this chemokine
can, by engaging other available receptors such as CCR3
and CCR1, result in increased recruitment of inflammatory
cells and production of pro-inflammatory cytokines within
the inflammatory reactions. These findings are potentially
relevant to the pathogenesis of BD, in which both a
Th1-driven response and hyperactivation of neutrophils
are thought to be crucially involved [3, 4]. Taken together,
these data suggest that a genetically determined
up-regulation of CCR5 ligands may be implicated in the
pathogenesis of vascular inflammation in BD.
A second aim of this study was to determine whether
CCR5D32 polymorphism might be associated with the
clinical expression of BD in our cohort of Italian patients.
However, when the frequencies of clinical manifestations
were compared between CC5RD32 allele carriers and
non-carriers, no differences were found, although our
study is probably not sufficiently powered to detect sig-
nificant associations between this CCR5 polymorphism
and clinical manifestations.
In conclusion, the results of this study suggest that
the CCR5!32 polymorphism may increase the suscepti-
bility to BD in Italian patients. Further studies
are required to replicate our findings in other popula-
tions and to better elucidate the role of chemokines
in the inflammatory events leading to vascular injury
in BD.
TABLE 2 Frequency of alleles, genotypes and carriage rates of CCR5D32 polymorphisms in patients with BD and in
controls
Variable BD (n=196) Controls (n=180) P OR (95% CI)
Allele
D32 24/392 (6.1) 10/360 (2.8) 0.020 2.28 (1.1, 4.8)
CCR5 368/392 (93.9) 350/360 (97.2)
Genotype
D32/D32 0/196 0/180 0.024
CCR5/D32 24/196 (12.2) 10/180 (5.6)
CCR5/CCR5 172/196 (87.8) 170/180 (94.4)
Carriage rate
D32/D32+CCR5/D32 24/196 (12.2) 10/180 (5.6) 0.024 2.37 (1.1, 5.1)
CCR5/CCR5 172/196 (87.8) 170/180 (94.4)
Values are the number/total number examined (%).
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Rheumatology key messages
. The CCR5D32 polymorphism may be associated
with an increased risk of developing Behc¸et’s dis-
ease (BD) in the Italian population.
. An association of CCR5D32 with subcutaneous
thrombophlebitis in patients with BD has been
found but was not statistically significant.
. Chemokines may have a role in the patho-
physiology of BD.
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